CS
CSBR.US Champions Oncology Inc
- Market cap
- USD 65.5M
- P/E
- -
- P/B
- 16.63x
- ROE
- -43.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is CSBR.US undervalued?
Graham numberThe Graham number of Champions Oncology Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Champions Oncology Inc fundamental analysis
No fundamental analysis for Champions Oncology Inc yet.
Champions Oncology Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceut…
Full company profileChampions Oncology Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Champions Oncology Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.4M | 20.2M | 27.1M | 32.1M | 41.0M | 49.1M | 53.9M | 50.2M | 56.9M | 59.4M | 60.9M |
| Gross Profit | 5.71M | 9.69M | 12.8M | 15.1M | 19.6M | 25.5M | 24.3M | 20.8M | 28.6M | 28.5M | 29.5M |
| Operating Income | -6.81M | -1.35M | 270K | -1.92M | 366K | 607K | -4.45M | -6.92M | 4.85M | -1.14M | -1.64M |
| EBITDA | -6.64M | -994K | 876K | -761K | 1.55M | 2.21M | -3.02M | -5.44M | 6.27M | 448K | -380K |
| Net Income | -6.88M | -1.48M | 128K | -2.09M | 362K | 548K | -5.34M | -7.28M | 4.70M | -1.18M | -1.70M |
| EPS | -0.63 | -0.13 | 0.01 | -0.18 | 0.02 | 0.04 | -0.39 | -0.54 | 0.33 | -0.08 | -0.12 |
| Balance Sheet | |||||||||||
| Total Assets | 8.01M | 8.08M | 11.3M | 20.8M | 27.6M | 35.4M | 34.3M | 26.1M | 32.3M | 27.0M | 33.3M |
| Total Liabilities | 7.61M | 8.10M | 9.03M | 15.7M | 20.2M | 26.3M | 29.7M | 28.0M | 28.6M | 22.9M | 28.8M |
| Shareholders' Equity | 400K | -25.0K | 2.24M | 5.10M | 7.43M | 9.10M | 4.64M | -1.90M | 3.77M | 3.94M | 3.89M |
| Cash & Short-term Investments | 3.30M | 856K | 3.24M | 8.34M | 4.69M | 9.01M | 10.1M | 2.62M | 9.79M | 4.87M | 4.36M |
| Total Debt | 63.0K | 45.0K | 16.0K | 3.80M | 9.60M | 9.47M | 8.60M | 7.43M | 6.11M | 4.51M | 11.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.84M | -1.23M | 1.86M | 2.91M | -1.68M | 6.50M | 3.96M | -6.14M | 7.39M | -4.47M | -1.97M |
| Capital Expenditure | 766K | 1.23M | 834K | 2.22M | 3.28M | 2.38M | 2.87M | 836K | 389K | 564K | 220K |
| Free Cash Flow | -3.61M | -2.46M | 1.03M | 685K | -4.96M | 4.11M | 1.08M | -6.97M | 7.00M | -5.04M | -2.19M |
| Ratios | |||||||||||
| ROE | -1,721.0% | - | 5.7% | -41.0% | 4.9% | 6.0% | -115.1% | - | 124.6% | -29.8% | -43.8% |
| ROA | -85.9% | -18.3% | 1.1% | -10.1% | 1.3% | 1.5% | -15.5% | -27.8% | 14.5% | -4.4% | -5.1% |
| Net Profit Margin | -44.7% | -7.3% | 0.5% | -6.5% | 0.9% | 1.1% | -9.9% | -14.5% | 8.3% | -2.0% | -2.8% |
| Debt to Equity | 0.16x | - | 0.01x | 0.74x | 1.29x | 1.04x | 1.85x | - | 1.62x | 1.15x | 2.82x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Champions Oncology Inc dividends
Champions Oncology Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:12 on Aug 12, 2015.
Who owns Champions Oncology Inc
- Insiders 26.83%
- Institutions 48.53%
- Public & others 24.63%
- Shares outstanding 13.9M
- Free float 6.04M
Top funds holding CSBR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 230K | 1.65% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 30.9K | 0.22% | -0.37% | Sep 2026 |
| iShares Micro-Cap ETF | 25.8K | 0.19% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 12.1K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 11.0K | 0.08% | 0.00% | Aug 2026 |
| Fidelity Series Total Market Index | 9.23K | 0.07% | 0.00% | Sep 2026 |
| Schwab Total Stock Market Index | 6.85K | 0.05% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 6.53K | 0.05% | 0.00% | Sep 2026 |
| Northern Small Cap Core I | 4.47K | 0.03% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 2.09K | 0.02% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 2.08K | 0.01% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 2.03K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding CSBR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Battery Management Corp | 2.42M | 17.40% | 0.00% | Jun 2026 |
| NEA Management Company, LLC | 1.71M | 12.31% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 301K | 2.17% | +0.61% | Jun 2026 |
| Tocqueville Asset Management L.P. | 296K | 2.12% | -7.51% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 235K | 1.69% | -2.85% | Jun 2026 |
| Bank of America Corp | 214K | 1.54% | +880.43% | Jun 2026 |
| Renaissance Technologies Corp | 139K | 1.00% | -4.47% | Jun 2026 |
| BlackRock Inc | 130K | 0.93% | +4.80% | Jun 2026 |
| Mink Brook Asset Management LLC | 111K | 0.80% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 76.3K | 0.55% | -1.14% | Jun 2026 |
| HighTower Advisors, LLC | 41.9K | 0.30% | +19.18% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 33.2K | 0.24% | +0.75% | Jun 2026 |
| Northern Trust Corp | 27.9K | 0.20% | -39.24% | Jun 2026 |
| State Street Corp | 26.2K | 0.19% | 0.00% | Jun 2026 |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 24.5K | 0.18% | +100.00% | Jun 2026 |
| Bank of New York Mellon Corp | 21.6K | 0.16% | 0.00% | Jun 2026 |
| Acadian Asset Management LLC | 20.5K | 0.15% | -3.75% | Jun 2026 |
| Citadel Advisors Llc | 18.3K | 0.13% | 0.00% | Jun 2026 |
| Essex Investment Management Company, LLC | 18.2K | 0.13% | -0.15% | Jun 2026 |
| Mesirow Fin Investmt Mgmt Intl Equity | 15.8K | 0.11% | 0.00% | Jun 2026 |
Champions Oncology Inc company profile
- Company name
- Champions Oncology Inc
- Ticker
- CSBR.US
- Exchange
- USA Stocks
- Listed since
- Jan 10, 2003
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 214
- Fiscal year end
- April
- Address
- One University Plaza, Hackensack, NJ, United States, 07601
- Phone
- 201 808 8400
- Website
- championsoncology.com
About Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Champions Oncology Inc management
5- Dr. Ronnie Morris M.D.Executive Chair · born 1966
- Mr. Robert BraininCEO & Director · born 1971
- Mr. David Barry Miller M.B.A.Chief Financial Officer · born 1969
- Dr. Maria Mancini Ph.D.Chief Operating Officer
- Dr. Marianna Zipeto Ph.D.Executive Vice President of Growth, Strategy & Enablement